Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
CONCLUSIONS: The results show a significant reduction of CMV viremia in D+/R+ and D-/R+ KTRs after introduction of 3-month prophylaxis with valganciclovir. Extension of CMV prophylaxis to 6 months in D+/R- was not associated with reduction in CMV viremia at 12 months after transplant.
.
PMID: 28601128 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Večerić-Haler Ž, Bizjak B, Romozi K, Arnol M Tags: Clin Nephrol Source Type: research
More News: Cytomegalovirus | Kidney Transplant | Kidney Transplantation | Study | Transplant Surgery | Transplants | Urology & Nephrology